EUVIMEDEUVIMED entdecken
Multizentrische Studie

The Fontan immunophenotype and post‐transplant outcomes in children: A multi‐institutional study

Benjamin S Mantell iD, Estela Azeka iD, Ryan S Cantor, Waldemar F Carlo iD, Maryanne Chrisant, John C Dykes, Timothy M Hoffman, James K Kirklin, Devin Koehl, Thomas J L'Ecuyer, Jennie M McAllister, Adriana C Prada-Ruiz und 1 weitere

Pediatric Transplantation · 2023

DOI: 10.1111/petr.14456 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Pediatric Transplantation, 2023. Verfasst von Benjamin S Mantell und 12 weiteren Autor:innen. Beteiligte Einrichtung: Division of Pediatric Cardiology, Morgan Stanley Children's Hospital, Columbia University Irving Medical Center of NewYork-Presbyterian, New York, Ne…. Hauptthemen laut MEDLINE: Protein-Losing Enteropathies, Lymphopenia, Fontan Procedure, Heart Transplantation. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 16 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Patients after Fontan palliation represent a growing pediatric population requiring heart transplant (HTx) and often have lymphopenia (L) and/or hypogammaglobinemia that may be exacerbated by protein‐losing enteropathy (PLE, P). The post‐HTx effects of this altered immune phenotype are not well studied.

Methods

In this study of the Pediatric Heart Transplant Society Registry, 106 Fontan patients who underwent HTx between 2005 and 2018 were analyzed. The impact of lymphopenia and PLE on graft survival, infection, rejection, and malignancy was analyzed at 1 and 5 years post‐HTx.

Results

The following combinations of lymphopenia and PLE were noted: +L+P, n = 37; +L−P, n = 23; −L+P, n = 10; and −L−P, n = 36. Graft survival between the groups was similar within the first year after transplant (+L+P: 86%, +L−P: 86%, −L+P: 87%, −L−P: 89%, p = .9). Freedom from first infection post‐HTx was greatest among −L−P patients compared to patients with either PLE, lymphopenia, or both; with a 22.1% infection incidence in the −L−P group and 41.4% in all others. These patients had a significantly lower infection rate in the first year after HTx (+L+P: 1.03, +L−P: 1, −L+P: 1.3, −L−P: 0.3 infections/year, p < .001) and were similar to a non‐single ventricle CHD control group (0.4 infections/year). Neither freedom from rejection nor freedom from malignancy 1 and 5 years post‐HTx, differed among the groups.

Conclusions

Fontan patients with altered immunophenotype, with lymphopenia and/or PLE, are at increased risk of infection post‐HTx, although have similar early survival and freedom from rejection and malignancy. These data may encourage alternative immunosuppression strategies and enhanced monitoring for this growing subset of patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Protein-Losing EnteropathiesLymphopeniaFontan ProcedureHeart TransplantationBone Marrow DiseasesNeoplasmsChildHumansImmunosuppression TherapyRetrospective Studies

Stichwörter der Autor:innen

PTLDgraft rejectionimmune responsesinfectious riskpediatric heart transplant

Autor:innen und Institutionen

  • Division of Pediatric Cardiology, Morgan Stanley Children's Hospital, Columbia University Irving Medical Center of NewYork-Presbyterian, New York, New York, USA.
  • Heart Institute (InCor), University of São Paulo Medical School, São Paulo, Brazil.
  • Kirklin Institute for Research in Surgical Outcomes, The University of Alabama at Birmingham, Birmingham, Alabama, USA.
  • Division of Pediatric Cardiology, Children's of Alabama, Birmingham, Alabama, USA.
  • The Heart Institute, Joe DiMaggio Children's Hospital, Hollywood, Florida, USA.
  • Division of Pediatric Cardiology, Lucile Packard Children's Hospital Stanford, Palo Alto, California, USA.

ORCID-Profile: Benjamin S Mantell, Estela Azeka, Waldemar F Carlo, Marc E Richmond

Zitieren

APA

Mantell, B. S., Azeka, E., Cantor, R. S., Carlo, W. F., Chrisant, M., Dykes, J. C., Hoffman, T. M., Kirklin, J. K., Koehl, D., L'Ecuyer, T. J., McAllister, J. M., Prada-Ruiz, A. C., & Richmond, M. E. (2023). The Fontan immunophenotype and post‐transplant outcomes in children: A multi‐institutional study. Pediatric Transplantation. https://doi.org/10.1111/petr.14456

Vancouver

Mantell BS, Azeka E, Cantor RS, Carlo WF, Chrisant M, Dykes JC, et al. The Fontan immunophenotype and post‐transplant outcomes in children: A multi‐institutional study. Pediatric Transplantation. 2023. doi:10.1111/petr.14456

BibTeX
@article{Mantell2023,
  author = {Mantell, Benjamin S and Azeka, Estela and Cantor, Ryan S and Carlo, Waldemar F and Chrisant, Maryanne and Dykes, John C and Hoffman, Timothy M and Kirklin, James K and Koehl, Devin and L'Ecuyer, Thomas J and McAllister, Jennie M and Prada-Ruiz, Adriana C and Richmond, Marc E},
  title = {The Fontan immunophenotype and post‐transplant outcomes in children: A multi‐institutional study},
  journal = {Pediatric Transplantation},
  year = {2023},
  doi = {10.1111/petr.14456}
}
Kostenlos starten →